Galectin Therapeutics Inc SEC filings GALT
Galectin Therapeutics Inc has 1,000 filings in SEC EDGAR's recent list, going back to Oct 18, 2011. Its latest annual report, Form ARS, was filed on Oct 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 10, 2026 | — |
| CORRESP | Letter to the SEC | Apr 8, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2026 | — |
| EFFECT | Filing | Apr 24, 2023 | — |
| CORRESP | Letter to the SEC | Apr 20, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2023 | — |
| EFFECT | Filing | May 21, 2020 | — |
| CORRESP | Letter to the SEC | May 19, 2020 | — |
| UPLOAD | Letter from the SEC | May 18, 2020 | — |
| EFFECT | Filing | Aug 22, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2019 | — |
| CORRESP | Letter to the SEC | Aug 20, 2019 | — |
| EFFECT | Filing | Apr 12, 2019 | — |
| CORRESP | Letter to the SEC | Apr 12, 2019 | — |
| CORRESP | Letter to the SEC | Apr 10, 2019 | — |
| CORRESP | Letter to the SEC | Apr 10, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2019 | — |
| EFFECT | Filing | Sep 10, 2018 | — |
| CORRESP | Letter to the SEC | Sep 6, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 10, 2018 | — |
| EFFECT | Filing | Jun 1, 2017 | — |
| CORRESP | Letter to the SEC | May 31, 2017 | — |
| UPLOAD | Letter from the SEC | May 30, 2017 | — |
| 25-NSE | Delisting notice | Mar 23, 2017 | — |
| 25-NSE | Delisting notice | Mar 23, 2017 | — |
| D | Filing | Jan 6, 2017 | — |
| D | Filing | Sep 28, 2016 | — |
| EFFECT | Filing | Sep 9, 2016 | — |
| CORRESP | Letter to the SEC | Sep 7, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2016 | — |
| CT ORDER | Filing | May 27, 2016 | — |
| EFFECT | Filing | Jan 12, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 8, 2016 | — |
| CORRESP | Letter to the SEC | Jan 8, 2016 | — |
| D | Filing | Dec 21, 2015 | — |
| CT ORDER | Filing | May 26, 2015 | — |
| NT 10-K | Nt-10k | Mar 16, 2015 | Dec 31, 2014 |
| EFFECT | Filing | Mar 31, 2014 | — |
| EFFECT | Filing | Jan 11, 2013 | — |
| CERTNAS | Auto-generated paper document | Mar 22, 2012 | — |
| 8-A12B/A | Amendment no. 1 to form 8-a | Mar 22, 2012 | — |
| EFFECT | Filing | Jan 27, 2012 | — |
| CT ORDER | Filing | Jan 4, 2012 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2011 | — |
| CORRESP | Letter to the SEC | Dec 19, 2011 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2011 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Norcross, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1133416
- Former names
- PRO PHARMACEUTICALS INC (until May 26, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.